Full Title
A Phase 2, Randomized, Open-label, Active-controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III Non-small Cell Lung CancerPurpose
[NOTE THAT ASTRAZENECA, THE MAKER OF DURVALUMAB, REQUESTS WE DO NOT SHARE ANY INFO THAT IS NOT ON CLINICALTRIALS.GOV]
Researchers are assessing JNJ-90301900 plus chemoradiation, followed by durvalumab, to treat lung cancer. The people in this study have stage 3 non-small cell lung cancer (NSCLC) that is inoperable (cannot be surgically removed).
If you take part in this study, you will get JNJ-90301900 injected into a tumor or cancerous lymph nodes. You will also have chemotherapy with carboplatin and paclitaxel, as well as radiation therapy.
Afterward, you will then get durvalumab immunotherapy. Carboplatin, paclitaxel, and durvalumab are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have inoperable stage 3 NSCLC that does not have EGFR or ALK mutations.
- Not have had anti-cancer medications within 3 years of starting the study treatment.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Matthew Bott’s office at 212-639-5944.